ProCE Banner Activity


Making Sense of the Expanding Options in Metastatic Colorectal Cancer Care: Part 1

Podcast Episodes

In this first of 2 episodes based on a live presentation on metastatic colorectal cancer (mCRC) care, listen as oncology experts discuss the latest evidence that informs how they select treatment regimens for patients with mCRC. Topics include how to implement recommended testing for mutations and biomarkers that impact mCRC, how to plan strategies for incorporating novel agents into treatment, and recommended strategies to identify and manage toxicities of novel agents for mCRC.

To access episode 2, click here.

Physician Assistants: maximum of 0.50 hours of AAPA Category 1 CME credits Registered Nurses: 0.50 Nursing contact hours, includes 0.50 hour of pharmacology credit

Released: March 21, 2022

Expiration: March 20, 2023

No longer available for credit.



Stephanie Andrews

Stephanie Andrews, MS, APRN-C

Nurse Practitioner
Department of Malignant Hematology
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida

Cathy Eng

Cathy Eng, MD

Professor of Medicine, Hematology, and Oncology
Gastrointestinal Cancer Research Program
Gastrointestinal Oncology
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, Tennessee

Joleen Hubbard

Joleen Hubbard, MD

Associate Professor
Gastrointestinal Oncologist
Medical Oncology
Mayo Clinic
Rochester, Minnesota


This program is cosupported by educational grants from Bristol-Myers Squibb; Eisai; and Merck Sharp & Dohme Corp.

This activity is supported by an educational grant from Merck Sharp & Dohme Corp.

Provided by

ProCE Banner


Merck Sharp & Dohme Corp.

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement recommended testing for mutations and biomarkers that impact mCRC

  • Plan strategies for incorporating novel agents into the treatment of patients with mCRC

  • Apply recommended strategies to identify and manage toxicities of novel agents for mCRC


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Ms Andrews: fees for non-CME/CE services: Genentech.

Dr Eng: consulting fees: Amgen, GlaxoSmithKline, Hoopika, Natera; contracted research (paid to institution): Merck, Pfizer.

Dr Hubbard: advisor: BeiGene; advisor/researcher: Bayer, Boston Biomedical, G1 Therapeutics, Hutchison MediPharma, Incyte, Merck, Pionyr Immunotherapeutics, Seagen, Senhwa Pharmaceuticals, Roche, Treos Bio, TriOncology, Trovogene.

Dr Moench: independent contractor: Merck.

None of the members of the PCE staff have any relevant relationships to disclose.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. Listen to the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the post-test and evaluation form

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 100%.

The estimated time to complete this activity is 0.50 hours.

Release date: March 21, 2022
Expiration date: March 20, 2023




The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.



Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 0.50, which includes 0.50 hours of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until March 20, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Susan Moench, PhD, PA-C, Edison, New Jersey

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.